Ming Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ming Wang has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Li Xu
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, 430030, China
5 shared publications - Xu Yu
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, 430030, China
5 shared publications - Ming Jiang
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China
4 shared publications - Yan Li
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China
4 shared publications - Cefan Zhou
Hubei University of Technology
3 shared publications - Jingfeng Tang
Hubei University of Technology
3 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1866353
Application and evaluation of nanopore targeted sequencing in the detection of bacterial and fungal pathogens in leukemia bloodstream infections
Objective: To evaluate the diagnostic performance and clinical impact of microbial nanopore-targeted sequencing (NTS) technology on pathogenic microorganisms in leukemia patients. Methods: In this retrospective observational study, we recruited 206 patients to study the effectiveness of NTS in the identification of infectious pathogens. The detection performance of NTS was compared with that of blood culture (BC). Results: The positive rate of NTS was significantly higher than that of BC [62.62% (129/206 cases) vs. 3.88% (8/206 cases)]. Compared with BC, the positive and negative percentage agreement of NTS were 87.50% (95%CI: 47.35–99.68%), (7 of 8 cases) and 38.38% (95%CI: 31.52–45.60%), (76 of 198 cases), respectively. The sensitivity of NTS for diagnosing bloodstream infections was 65.32% (95%CI: 56.21–73.69%), (81/124), which was significantly higher than BC [6.45% (95%CI: 2.84–12.13%), (8/124)], P < 0.001. The specificity of NTS was 41.46% (95%CI: 30.17–53.52%%), (34/82), and that of BC was [100%(95%CI: 95.56–100.00%) (82/82)]. The medication of 32 participants (24.81% [32/129]) was modified by NTS results. Among 206 participants, 29 cases who adjusted their medication based on NTS results showed improved clinical outcomes. Conclusion: NTS increases pathogen-detection yield but has low specificity and can be used as an adjunctive diagnostic method for leukemia BSI.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1866353
Open AccessApplication and evaluation of nanopore targeted sequencing in the detection of bacterial and fungal pathogens in leukemia bloodstream infections
Objective: To evaluate the diagnostic performance and clinical impact of microbial nanopore-targeted sequencing (NTS) technology on pathogenic microorganisms in leukemia patients. Methods: In this retrospective observational study, we recruited 206 patients to study the effectiveness of NTS in the identification of infectious pathogens. The detection performance of NTS was compared with that of blood culture (BC). Results: The positive rate of NTS was significantly higher than that of BC [62.62% (129/206 cases) vs. 3.88% (8/206 cases)]. Compared with BC, the positive and negative percentage agreement of NTS were 87.50% (95%CI: 47.35–99.68%), (7 of 8 cases) and 38.38% (95%CI: 31.52–45.60%), (76 of 198 cases), respectively. The sensitivity of NTS for diagnosing bloodstream infections was 65.32% (95%CI: 56.21–73.69%), (81/124), which was significantly higher than BC [6.45% (95%CI: 2.84–12.13%), (8/124)], P < 0.001. The specificity of NTS was 41.46% (95%CI: 30.17–53.52%%), (34/82), and that of BC was [100%(95%CI: 95.56–100.00%) (82/82)]. The medication of 32 participants (24.81% [32/129]) was modified by NTS results. Among 206 participants, 29 cases who adjusted their medication based on NTS results showed improved clinical outcomes. Conclusion: NTS increases pathogen-detection yield but has low specificity and can be used as an adjunctive diagnostic method for leukemia BSI.
- Open Access
- 6 September 2026
- Published by Elsevier in SSRN Electronic Journal
Bioinspired fluid membrane-functionalized micro/nanostructured interfaces for synergistically enhanced capture of circulating tumor cells
Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition downregulate epithelial markers and upregulate mesenchymal markers, introducing heterogeneity that complicates reliable identification of CTCs. In this study, we rationally designed a rose petal-derived micro-structured microchip featuring in situ grown ZnO nanorods, simultaneously functionalized with THP-1 cell membrane vesicles (TMVs) and multivalent aptamers, denoted as Mix-TMVs-RPD-ZnO-Chip. The replicated micro-structure establishes a dimensionally matched confinement that enhances contact area between CTCs and the functionalized surface. The TMVs effectively reduce non-specific adsorption of leukocyte cells. In parallel, the SYL3C and SJ3C2 aptamers balance binding thermodynamics and kinetics for epithelial CTCs (E-CTCs), while the NC3S aptamer enables capture of mesenchymal CTCs (M-CTCs). This design exhibits high-affinity towards E-CTCs and M-CTCs with dissociation constants of 6.125 nM and 22.46 nM, respectively, achieving capture efficiencies exceeding 90.8% and 87.1% within 45 min. The Mix-TMVs-RPD-ZnO-Chip also allows downstream analysis after release with high cell viability. Varying numbers of CTCs are successfully captured from blood samples of 48 patients with lung, colorectal, and breast cancer. Single-cell sequencing further confirms KRAS and p53 gene mutations in the captured CTCs. Overall, this approach holds potential for clinical trials in CTCs capture and analysis, promising disease diagnosis and guidance in clinical treatment.
- 6 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBioinspired fluid membrane-functionalized micro/nanostructured interfaces for synergistically enhanced capture of circulating tumor cells
Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition downregulate epithelial markers and upregulate mesenchymal markers, introducing heterogeneity that complicates reliable identification of CTCs. In this study, we rationally designed a rose petal-derived micro-structured microchip featuring in situ grown ZnO nanorods, simultaneously functionalized with THP-1 cell membrane vesicles (TMVs) and multivalent aptamers, denoted as Mix-TMVs-RPD-ZnO-Chip. The replicated micro-structure establishes a dimensionally matched confinement that enhances contact area between CTCs and the functionalized surface. The TMVs effectively reduce non-specific adsorption of leukocyte cells. In parallel, the SYL3C and SJ3C2 aptamers balance binding thermodynamics and kinetics for epithelial CTCs (E-CTCs), while the NC3S aptamer enables capture of mesenchymal CTCs (M-CTCs). This design exhibits high-affinity towards E-CTCs and M-CTCs with dissociation constants of 6.125 nM and 22.46 nM, respectively, achieving capture efficiencies exceeding 90.8% and 87.1% within 45 min. The Mix-TMVs-RPD-ZnO-Chip also allows downstream analysis after release with high cell viability. Varying numbers of CTCs are successfully captured from blood samples of 48 patients with lung, colorectal, and breast cancer. Single-cell sequencing further confirms KRAS and p53 gene mutations in the captured CTCs. Overall, this approach holds potential for clinical trials in CTCs capture and analysis, promising disease diagnosis and guidance in clinical treatment.
- Open Access
- 9 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (7) , e72101
Efficacy and Safety of rhIL ‐11 in the Treatment of Cancer Therapy‐Induced Thrombocytopenia: A Multicenter Retrospective Study
Objective: This real‐world study aimed to investigate the cancer therapy‐induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in its management. Methods: Retrospective analysis included 12,431 CTIT patients treated with rhIL‐11 across 58 Chinese centers (July 2023–June 2024). Multivariate logistic regression analysis identified CTIT risk factors. Treatment outcomes and adverse events (AEs) were assessed. Results: Independent CTIT risk factors included advanced age, medical history, prior myelosuppression, tumor type, bone marrow involvement, and previous anti‐tumor therapy. RhIL‐11 demonstrated significant thrombopoietic effects, with a mean treatment duration of 6.79 ± 2.59 days. Platelet (PLT) recovery to 50 × 10 9 /L and 100 × 10 9 /L was 4.60 ± 4.40 days and 7.68 ± 5.09 days, respectively. Hematologic malignancy patients required longer treatment and slower PLT recovery compared to those with solid tumors. Urologic and head/neck malignancy patients had faster recovery, while uterine, colorectal, and liver cancer patients exhibited poorer outcomes. Fluoropyrimidine monotherapy delayed PLT recovery compared to platinum‐, taxane‐, anthracycline‐based regimens, or gemcitabine/platinum combinations (all p < 0.05). Furthermore, patients with “impaired” PLT recovery capacity or grade IV CTIT demonstrated longer treatment and PLT recovery times, while grade I/III CTIT was associated with higher PLT recovery response rates. AEs occurred in 28.9% of patients, primarily mild fatigue (15.3%) and edema (7.5%). COVID‐19 infection correlated with prolonged treatment duration and delayed PLT normalization. Conclusion: This large‐scale real‐world study confirms the efficacy and safety of rhIL‐11 in CTIT management. Treatment responses vary slightly across patient subgroups, but tolerability remains acceptable. Findings emphasize individualized CTIT strategies and proactive AEs monitoring.
- 9 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (7) , e72101
Open AccessEfficacy and Safety of rhIL ‐11 in the Treatment of Cancer Therapy‐Induced Thrombocytopenia: A Multicenter Retrospective Study
Objective: This real‐world study aimed to investigate the cancer therapy‐induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in its management. Methods: Retrospective analysis included 12,431 CTIT patients treated with rhIL‐11 across 58 Chinese centers (July 2023–June 2024). Multivariate logistic regression analysis identified CTIT risk factors. Treatment outcomes and adverse events (AEs) were assessed. Results: Independent CTIT risk factors included advanced age, medical history, prior myelosuppression, tumor type, bone marrow involvement, and previous anti‐tumor therapy. RhIL‐11 demonstrated significant thrombopoietic effects, with a mean treatment duration of 6.79 ± 2.59 days. Platelet (PLT) recovery to 50 × 10 9 /L and 100 × 10 9 /L was 4.60 ± 4.40 days and 7.68 ± 5.09 days, respectively. Hematologic malignancy patients required longer treatment and slower PLT recovery compared to those with solid tumors. Urologic and head/neck malignancy patients had faster recovery, while uterine, colorectal, and liver cancer patients exhibited poorer outcomes. Fluoropyrimidine monotherapy delayed PLT recovery compared to platinum‐, taxane‐, anthracycline‐based regimens, or gemcitabine/platinum combinations (all p < 0.05). Furthermore, patients with “impaired” PLT recovery capacity or grade IV CTIT demonstrated longer treatment and PLT recovery times, while grade I/III CTIT was associated with higher PLT recovery response rates. AEs occurred in 28.9% of patients, primarily mild fatigue (15.3%) and edema (7.5%). COVID‐19 infection correlated with prolonged treatment duration and delayed PLT normalization. Conclusion: This large‐scale real‐world study confirms the efficacy and safety of rhIL‐11 in CTIT management. Treatment responses vary slightly across patient subgroups, but tolerability remains acceptable. Findings emphasize individualized CTIT strategies and proactive AEs monitoring.
- Open Access
- 9 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (49) , e75983
Machine Learning‐Enhanced Ultrasensitive Immuno‐CRISPR Array Facilitates Early Diagnosis of Alzheimer's Disease by Detecting Multiple Plasma Biomarkers
Early and accurate diagnosis of Alzheimer's disease (AD) remains a significant challenge due to the multifactorial and dynamic nature of its pathology. Although plasma‐based biomarkers such as amyloid‐β (Aβ) and phosphorylated tau (p‐tau) have shown promise as diagnostic indicators, current single‐biomarker detection techniques lack the requisite sensitivity and specificity for early‐stage diagnosis. Here, we present the development of an u ltrasensitive C RISPR‐based m ulti‐protein d etection a rray (UCMDA) capable of concurrently detecting six core AD biomarkers, including Aβ 40 , Aβ 42 , p‐tau 181 , p‐tau 217 , p‐tau 231 , and p‐tau 396,404 . By integrating antibody pair‐based multiplex recombinase polymerase amplification (RPA) with spatially encoded CRISPR‐Cas12a detection, the UCMDA achieves a detection limit of 1 fg/mL, which is 10 000‐fold more sensitive than conventional ELISA. Clinical validation in a cohort of 155 plasma samples demonstrated that logistic regression (LR)‐based integration of the six biomarkers significantly enhanced diagnostic performance, with the multi‐biomarker model substantially outperforming single‐biomarker approaches in diagnosing AD‐MCI and AD. This platform offers a scalable, cost‐effective, and minimally invasive strategy for early detection and disease monitoring. This work highlights the potential of CRISPR‐based multiplex protein detection technologies combined with machine learning‐assisted analysis to enhance the precision of diagnosing neurodegenerative disorders.
- 9 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (49) , e75983
Open AccessMachine Learning‐Enhanced Ultrasensitive Immuno‐CRISPR Array Facilitates Early Diagnosis of Alzheimer's Disease by Detecting Multiple Plasma Biomarkers
Early and accurate diagnosis of Alzheimer's disease (AD) remains a significant challenge due to the multifactorial and dynamic nature of its pathology. Although plasma‐based biomarkers such as amyloid‐β (Aβ) and phosphorylated tau (p‐tau) have shown promise as diagnostic indicators, current single‐biomarker detection techniques lack the requisite sensitivity and specificity for early‐stage diagnosis. Here, we present the development of an u ltrasensitive C RISPR‐based m ulti‐protein d etection a rray (UCMDA) capable of concurrently detecting six core AD biomarkers, including Aβ 40 , Aβ 42 , p‐tau 181 , p‐tau 217 , p‐tau 231 , and p‐tau 396,404 . By integrating antibody pair‐based multiplex recombinase polymerase amplification (RPA) with spatially encoded CRISPR‐Cas12a detection, the UCMDA achieves a detection limit of 1 fg/mL, which is 10 000‐fold more sensitive than conventional ELISA. Clinical validation in a cohort of 155 plasma samples demonstrated that logistic regression (LR)‐based integration of the six biomarkers significantly enhanced diagnostic performance, with the multi‐biomarker model substantially outperforming single‐biomarker approaches in diagnosing AD‐MCI and AD. This platform offers a scalable, cost‐effective, and minimally invasive strategy for early detection and disease monitoring. This work highlights the potential of CRISPR‐based multiplex protein detection technologies combined with machine learning‐assisted analysis to enhance the precision of diagnosing neurodegenerative disorders.
- 12 January 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (3) , 2214-2224
Multistage Cascade-Hierarchical Nucleic Acid Amplification for Label-Free Ultrasensitive Electrochemical Sensing of Tumor-Associated Extracellular Vesicles
Extracellular vesicles (EVs) are emerging as promising biomarkers for cancer diagnosis, yet the scarcity of tumor-derived EVs (tEVs) in biofluids in early disease stages hampers their sensitive and accurate quantification. Herein, we report an ultrasensitive electrochemical biosensor for highly specific detection of circulating tEVs, which integrates rolling circle amplification, cascade primer exchange reactions, and hierarchically self-assembled DNA architectures (HSDA). Target tEVs are recognized by multivalent aptamers, triggering the release of complementary DNA (cDNA) strands from the aptamer/cDNA duplex. The released cDNAs hybridize with HSDA, and the resulting cDNA/HSDA complex is subsequently immobilized on the electrode surface with the aid of a DNA probe, yielding a strong electrochemical response. The multistage cascade-hierarchical nucleic acid amplification markedly improves detection sensitivity, reaching a limit of 251 particles mL-1 (i.e., < 3 tEVs per 10 μL), corresponding to a 47.6-fold enhancement over the non-HSDA-mediated amplification approach. In addition, we can track the dynamic changes in epithelial cell adhesion molecule-positive tEVs (EpCAM+ tEVs) under drug treatment. Furthermore, EpCAM+ tEVs can distinguish cancer patients from healthy individuals, underscoring the potential of circulating tEVs for clinical diagnosis and therapy monitoring.
- 12 January 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (3) , 2214-2224
Multistage Cascade-Hierarchical Nucleic Acid Amplification for Label-Free Ultrasensitive Electrochemical Sensing of Tumor-Associated Extracellular Vesicles
Extracellular vesicles (EVs) are emerging as promising biomarkers for cancer diagnosis, yet the scarcity of tumor-derived EVs (tEVs) in biofluids in early disease stages hampers their sensitive and accurate quantification. Herein, we report an ultrasensitive electrochemical biosensor for highly specific detection of circulating tEVs, which integrates rolling circle amplification, cascade primer exchange reactions, and hierarchically self-assembled DNA architectures (HSDA). Target tEVs are recognized by multivalent aptamers, triggering the release of complementary DNA (cDNA) strands from the aptamer/cDNA duplex. The released cDNAs hybridize with HSDA, and the resulting cDNA/HSDA complex is subsequently immobilized on the electrode surface with the aid of a DNA probe, yielding a strong electrochemical response. The multistage cascade-hierarchical nucleic acid amplification markedly improves detection sensitivity, reaching a limit of 251 particles mL-1 (i.e., < 3 tEVs per 10 μL), corresponding to a 47.6-fold enhancement over the non-HSDA-mediated amplification approach. In addition, we can track the dynamic changes in epithelial cell adhesion molecule-positive tEVs (EpCAM+ tEVs) under drug treatment. Furthermore, EpCAM+ tEVs can distinguish cancer patients from healthy individuals, underscoring the potential of circulating tEVs for clinical diagnosis and therapy monitoring.
- Open Access
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1660317
The role of insulin resistance in the relationship between uric acid and the severity of coronary artery disease: evidence from real-world data
Background: The link between uric acid (UA) and cardiovascular diseases is debated, with insulin resistance possibly affecting this relationship. The triglyceride-glucose (TyG) index is a recognized marker for insulin resistance. However, the combined effect of different levels of UA and TyG on the severity of coronary artery disease (CAD) remains unclear.Methods: A cohort of 1,835 patients with newly diagnosed CAD was divided into single-vessel (743 patients) and multi-vessel (1,092 patients) CAD groups. The study utilized logistic regression, restricted cubic spline (RCS), and extreme gradient boosting (XGBoost) models to explore the associations between UA, TyG, and multi-vessel CAD. Interaction analysis assessed potential additive and multiplicative interactions. A mediation analysis was performed to assess the indirect effects of TyG and UA on the severity of CAD.Results: The TyG > 9.33 and non-HUA group is linked to a higher risk of multi-vessel CAD (OR 1.41, 95% CI 1.08–1.85), while the TyG ≤ 9.33 and HUA group shows no significant association (OR 1.08, 95% CI 0.76–1.53). The feature importance analysis, using the XGBoost model, demonstrated that TyG has a higher predictive value for multi-vessel CAD. No nonlinear correlations were observed for RCS. No notable additive or multiplicative interactions were detected between TyG and UA. Mediation analysis revealed that TyG significantly mediated the relationship between UA and multi-vessel CAD, with a proportion mediated of 18.89% (p = 0.026). In contrast, UA did not significantly mediate the TyG–CAD relationship (p = 0.082).Conclusion: The TyG index correlated more strongly with multi-vessel CAD compared to UA. Hyperuricemia correlated with multi-vessel CAD exclusively at elevated TyG levels, with TyG mediating the link between uric acid and CAD severity.
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1660317
Open AccessThe role of insulin resistance in the relationship between uric acid and the severity of coronary artery disease: evidence from real-world data
Background: The link between uric acid (UA) and cardiovascular diseases is debated, with insulin resistance possibly affecting this relationship. The triglyceride-glucose (TyG) index is a recognized marker for insulin resistance. However, the combined effect of different levels of UA and TyG on the severity of coronary artery disease (CAD) remains unclear.Methods: A cohort of 1,835 patients with newly diagnosed CAD was divided into single-vessel (743 patients) and multi-vessel (1,092 patients) CAD groups. The study utilized logistic regression, restricted cubic spline (RCS), and extreme gradient boosting (XGBoost) models to explore the associations between UA, TyG, and multi-vessel CAD. Interaction analysis assessed potential additive and multiplicative interactions. A mediation analysis was performed to assess the indirect effects of TyG and UA on the severity of CAD.Results: The TyG > 9.33 and non-HUA group is linked to a higher risk of multi-vessel CAD (OR 1.41, 95% CI 1.08–1.85), while the TyG ≤ 9.33 and HUA group shows no significant association (OR 1.08, 95% CI 0.76–1.53). The feature importance analysis, using the XGBoost model, demonstrated that TyG has a higher predictive value for multi-vessel CAD. No nonlinear correlations were observed for RCS. No notable additive or multiplicative interactions were detected between TyG and UA. Mediation analysis revealed that TyG significantly mediated the relationship between UA and multi-vessel CAD, with a proportion mediated of 18.89% (p = 0.026). In contrast, UA did not significantly mediate the TyG–CAD relationship (p = 0.082).Conclusion: The TyG index correlated more strongly with multi-vessel CAD compared to UA. Hyperuricemia correlated with multi-vessel CAD exclusively at elevated TyG levels, with TyG mediating the link between uric acid and CAD severity.
- 14 May 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (13) , 3185-3196
An integrated microfluidic chip for synchronous drug loading, separation and detection of plasma exosomes
A microfluidic chip integrating a 3D macroporous scaffold and magnetoresponsive electrode achieves exosome isolation, electrochemical detection, and doxorubicin loading, offering a seamless platform for analysis and therapeutic delivery.
- 14 May 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (13) , 3185-3196
An integrated microfluidic chip for synchronous drug loading, separation and detection of plasma exosomes
A microfluidic chip integrating a 3D macroporous scaffold and magnetoresponsive electrode achieves exosome isolation, electrochemical detection, and doxorubicin loading, offering a seamless platform for analysis and therapeutic delivery.
- Open Access
- 1 January 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 43, 292-304
Rapid and unbiased enrichment of extracellular vesicles via a meticulously engineered peptide
Extracellular vesicles (EVs) have garnered significant attention in biomedical applications. However, the rapid, efficient, and unbiased separation of EVs from complex biological fluids remains a challenge due to their heterogeneity and low abundance in biofluids. Herein, we report a novel approach to reconfigure and modify an artificial insertion peptide for the unbiased and rapid isolation of EVs in 20 min with ∼80% recovery in neutral conditions. Moreover, the approach demonstrates exceptional anti-interference capability and achieves a high purity of EVs comparable to standard ultracentrifugation and other methods. Importantly, the isolated EVs could be directly applied for downstream protein and nucleic acid analyses, including proteomics analysis, exome sequencing analysis, as well as the detection of both epidermal growth factor receptor (EGFR) and V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) gene mutation in clinical plasma samples. Our approach offers great possibilities for utilizing EVs in liquid biopsy, as well as in various other biomedical applications.
- 1 January 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 43, 292-304
Open AccessRapid and unbiased enrichment of extracellular vesicles via a meticulously engineered peptide
Extracellular vesicles (EVs) have garnered significant attention in biomedical applications. However, the rapid, efficient, and unbiased separation of EVs from complex biological fluids remains a challenge due to their heterogeneity and low abundance in biofluids. Herein, we report a novel approach to reconfigure and modify an artificial insertion peptide for the unbiased and rapid isolation of EVs in 20 min with ∼80% recovery in neutral conditions. Moreover, the approach demonstrates exceptional anti-interference capability and achieves a high purity of EVs comparable to standard ultracentrifugation and other methods. Importantly, the isolated EVs could be directly applied for downstream protein and nucleic acid analyses, including proteomics analysis, exome sequencing analysis, as well as the detection of both epidermal growth factor receptor (EGFR) and V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) gene mutation in clinical plasma samples. Our approach offers great possibilities for utilizing EVs in liquid biopsy, as well as in various other biomedical applications.
- 1 August 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (36) , 9018-9029
Intravascular elimination of circulating tumor cells and cascaded embolization with multifunctional 3D tubular scaffolds
Gold nanotube-coated 3D tubular scaffolds implanted in vivo for intravascular elimination of circulating tumor cells and cascaded tumor embolization.
- 1 August 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (36) , 9018-9029
Intravascular elimination of circulating tumor cells and cascaded embolization with multifunctional 3D tubular scaffolds
Gold nanotube-coated 3D tubular scaffolds implanted in vivo for intravascular elimination of circulating tumor cells and cascaded tumor embolization.
- 2 July 2024
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 135 (7)
The bacterial and fungal profiles of patients hospitalized with non-COVID-19 lower respiratory tract infections in Wuhan, China, 2019–2021
A severe lockdown occurred in Wuhan during the COVID-19 pandemic, followed by a remission phase in the pandemic’s aftermath. This study analyzed the bacterial and fungal profiles of respiratory pathogens in patients hospitalized with non-COVID-19 lower respiratory tract infections (LRTIs) during this period to determine the pathogen profile distributions in different age groups and hospital departments in Wuhan. We collected reports of pathogen testing in the medical records of patients hospitalized with non-COVID-19 LRTI between 2019 and 2021. These cases were tested for bacterial and fungal pathogens using 16S and internal transcribed spacer sequencing methods on bronchoalveolar lavage fluid samples. The study included 1368 cases. The bacteria most commonly identified were Streptococcus pneumoniae (12.50%) and Mycoplasma pneumoniae (8.33%). The most commonly identified fungi were Aspergillus fumigatus (2.49%) and Pneumocystis jirovecii (1.75%). Compared to 2019, the S. pneumoniae detection rates increased significantly in 2021, and those of M. pneumoniae decreased. Streptococcus pneumoniae was detected mainly in children. The detection rates of almost all fungi were greater in the respiratory Intensive Care Unit compared to respiratory medicine. Streptococcus pneumoniae and M. pneumoniae were detected more frequently in the pediatric department. Before and after the COVID-19 outbreak, a change in the common pathogen spectrum was detected in patients with non-COVID-19 in Wuhan, with the greatest change occurring among children. The major pathogens varied by the patient’s age and the hospital department.
- 2 July 2024
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 135 (7)
The bacterial and fungal profiles of patients hospitalized with non-COVID-19 lower respiratory tract infections in Wuhan, China, 2019–2021
A severe lockdown occurred in Wuhan during the COVID-19 pandemic, followed by a remission phase in the pandemic’s aftermath. This study analyzed the bacterial and fungal profiles of respiratory pathogens in patients hospitalized with non-COVID-19 lower respiratory tract infections (LRTIs) during this period to determine the pathogen profile distributions in different age groups and hospital departments in Wuhan. We collected reports of pathogen testing in the medical records of patients hospitalized with non-COVID-19 LRTI between 2019 and 2021. These cases were tested for bacterial and fungal pathogens using 16S and internal transcribed spacer sequencing methods on bronchoalveolar lavage fluid samples. The study included 1368 cases. The bacteria most commonly identified were Streptococcus pneumoniae (12.50%) and Mycoplasma pneumoniae (8.33%). The most commonly identified fungi were Aspergillus fumigatus (2.49%) and Pneumocystis jirovecii (1.75%). Compared to 2019, the S. pneumoniae detection rates increased significantly in 2021, and those of M. pneumoniae decreased. Streptococcus pneumoniae was detected mainly in children. The detection rates of almost all fungi were greater in the respiratory Intensive Care Unit compared to respiratory medicine. Streptococcus pneumoniae and M. pneumoniae were detected more frequently in the pediatric department. Before and after the COVID-19 outbreak, a change in the common pathogen spectrum was detected in patients with non-COVID-19 in Wuhan, with the greatest change occurring among children. The major pathogens varied by the patient’s age and the hospital department.